NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories

  • Giuseppe Vergaro*
  • , Francesco Gentile
  • , Laura M. G. Meems
  • , Alberto Aimo
  • , James L. Januzzi Jr.
  • , A. Mark Richards
  • , Carolyn S. P. Lam
  • , Roberto Latini
  • , Lidia Staszewsky
  • , Inder S. Anand
  • , Jay N. Cohn
  • , Thor Ueland
  • , Lars Gullestad
  • , Pal Aukrust
  • , Hans-Peter Brunner-La Rocca
  • , Antoni Bayes-Genis
  • , Josep Lupón
  • , Akiomi Yoshihisa
  • , Yasuchika Takeishi
  • , Michael Egstrup
  • Ida Gustafsson, Hanna K. Gaggin, Kai M. Eggers, Kurt Huber, Greg D. Gamble, Lieng H. Ling, Kui Tong Gerard Leong, Poh Shuah Daniel Yeo, Hean Yee Ong, Lur Jaufeerally, Tze P. Ng, Richard Troughton, Robert N. Doughty, Gerry Devlin, Mayanna Lund, Alberto Giannoni, Claudio Passino, Rudolf A. de Boer, Michele Emdin
*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

52 Citations (Scopus)
370 Downloads (Pure)

Abstract

OBJECTIVES

The goal of this study was to assess the predictive power of N-terminal pro–B-type natriuretic peptide (NT-proBNP) and the decision cutoffs in heart failure (HF) across body mass index (BMI) categories.

BACKGROUND 

Concentrations of NT-proBNP predict outcome in HF. Although the influence of BMI to reduce levels of NT-proBNP is known, the impact of obesity on prognostic value remains uncertain.

METHODS

Individual data from the BIOS (Biomarkers In Heart Failure Outpatient Study) consortium were analyzed. Patients with stable HF were classified as underweight (BMI = 40 kg/m(2)) obese. The prognostic rote of NT-proBNP was tested for the endpoints of all-cause and cardiac death.

RESULTS

The study population included 12,763 patients (mean age 66 +/- 12 years; 25% women; mean left ventricular ejection fraction 33% 113%). Most patients were overweight (n = 5,176), followed by normal weight (n = 4,299), mildly obese (n = 2,157), moderately obese (n = 612), severely obese (n = 314), and underweight (n = 205). NT-proBNP inversely correlated with BMI (beta = -0.174 for 1 kg/m(2); P < 0.001). Adding NT-proBNP to clinical models improved risk prediction across BMI categories, with the exception of severely obese patients. The best cutoffs of NT-proBNP for 5-year all-cause death prediction were lower as BMI increased (3,785 ng/L, 2,193 ng/L, 1,554 ng/L, 1,045 ng/L, 755 ng/L, and 879 ng/L, for underweight, normal weight, overweight, and mildly, moderately, and severely obese patients, respectively) and were higher in women than in men.

CONCLUSIONS

NT-proBNP maintains its independent prognostic value up to 40 kg/m(2) BMI, and tower optimal risk-prediction cutoffs are observed in overweight and obese patients.

Original languageEnglish
Pages (from-to)653-663
Number of pages11
JournalJACC. Heart failure
Volume9
Issue number9
DOIs
Publication statusPublished - Sept-2021

Keywords

  • body mass index
  • chronic heart failure
  • NT-proBNP
  • obesity
  • outcome
  • BRAIN NATRIURETIC PEPTIDE
  • REDUCED EJECTION FRACTION
  • SENSITIVE TROPONIN-T
  • OBESITY
  • ASSOCIATION
  • MORTALITY
  • IMPACT
  • TRIAL
  • MECHANISMS
  • PHENOTYPES

Fingerprint

Dive into the research topics of 'NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories'. Together they form a unique fingerprint.

Cite this